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There is no essential difference between thrombolysis and fibrinolysis.
The use of these two different words in the literature was necessary for
practical reasons. We use the expression oC thrombolysis" clinically. The
term "fibrinolysis" has been used for the lytic substrates of fibrin in vitro
by ASTRUP, GROSS and others. It is better used because the blood clotting
thrombus can be dissolved by the lysis of fibrin. The so·called mixed
thrombus is composed of cellular elements, particularly containing many
platelets. Further, these cellular components can hardly be influenced by
plasmin (fibrinolysin), or other proteolytic substance. Some problems
of lysis with fibrinolytic substances may be solved using radioactive PSI
streptokinase and by labelling clot autoradiographically. It is also possible
to label fibrin by radioactive iodine and to observe the fibrinolysis.
Enhanced .. fibrinolysis" is very often accompanied by enhanced
fibrinogenolysis. It should be stressed, furthermore, that the clinical
hemorrhagic diathesis which we see is not due to lysis of fibrin, but to
proteolytic change in the clotted fibrin.
One has noted in several cases associated with operation or delivery
that not only is fibrin deficient, but also other important blood clotting
factors, e. g., Factors V or VII are altered.
GOETHE has said that the history of a science is the science in itself.
Hence I will make a brief description of the history of" fibrinolysis". In
the 4th century B. C. HIPPOCRATES had already made observations which
could have been related to fibrinolysis. Later, in the 17th century MAL-
PIGHI, and DENIS in 1838, had noted that in some diseases blood would
not coagulate. The term "fibrinolysis" as such was first used by DASTRE
(1883). NOLF (1905) and OPIC (1911) have written on proteases in serum,
TILLETT (1933) on a fibrinolytic substance, MILSTONE (1941) on an agent
of indirect effect, CHRISTENSEN (1945) on plasmazymogen (plasminogen)
and INNERFIELD (1950) on trypsin. In 1955 TILLETT gave streptokinase
intravenously, in 1957 CLIFFTON plasmin intravenously, while SEEGERS
429
1
Szirmai: Various aspects of thrombolysis and fibrinolysis
Produced by The Berkeley Electronic Press, 1969
430 E. SZIR~IAI
injected "Thrombin E". So besides plasmin (or activators of plasminogens)
some other proteases have also been applied to clinical use. TILLETT (1933)
was the first to observe that filtrate of some haemolytic streptococci
can dissolve human blood clots, but intensive research in this field began
only in 1945. SZIRMAI in 1955 published a scheme from which it is very easy
to study fibrinolysis. (Table 1)
Fibrinolytic processes can be divided into four phases, viz: pre, 1st,
2nd and 3rd phase3. The pre-phase is a study of formation of different
activators and inhibitors. The first phase consists of the activation of
profibrinolysin, the second of the formation of fibrinolysin and the third
of thrombolysis,
As activators of fibrinolysis there are physiological and foreign-body
compounds which are of therapeutic me. According to the great Swiss
haematologist, R. FEISSLY, who died in January, 1966, polybrenes seem
to be excellent activators of fibrinolysis.
Concerning inhibitors of fibrinolysis, we again have two groups as
w~th the activators, i. e., physiological and therapeutic substances. In the
second group we have E-aminocaproic acid, inhibitor of soya, cystein and
mercaptol + tanolamin, although there are not many data relating to
these latter substances. With fibrinolysis and blood-clotting we note the
formation of a proteolytic ferment, i. e., thrombin which decomposes
fibrin into small units, viz: fibrin, polypeptide. The enzyme of fibrino-
lysis, fibrinolysin, also decomposes fibrin, but into different polypeptides.
Both proteolytic ferments are found in plasma in their inactive pre.phases
which are activated by the influence of tissue. and blood-activators.
There are many papers relating to methods of determination of
fi brinolysin.
I will now discuss the principal data relating to therapeutic aspects of
fi brinolysis.
Treatment by Fibrinolytic Agents
For clinical purposes fibrinolytic agents may be divided into two
grups, viz: those used locally and those used parenterally.
In treating patients with these agents, especially parenterally, the
following should be taken into consideration:
( 1) The mechanism of the effect of the preparation.
( 2) The :nethod of effective treatment and of its control.
( 3) Indications for treatment at a given time.
( 4) Contra-indications.
( 5) Possible side.effects, especially haemorrhage and its treatment
by fibrinolysin-antagonists.
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Table I Schema of the Fibrinolysis after SZIRMAI (1961)
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Local Fibrinolytic Therapy
Antibiotics become less useful when applied locally because of the
increase of resistant colonies of proteus, pyocyaneus, etc.. to antibiotics.
However, fibrinolytic therapy using streptokinase or streptodornase be-
comes more useful. The lytic substance of the steptococcus from which
streptokinase and streptodornase are prepared promotes the inflammatory
reaction of the organism, because the formation of fibrin and leukocytosis
inhibit diffuse infiltration of the tissues. In our clinic for over 11 years
we have used streptokinase and streptodornase with good effect in the
toilet of wounds. Unfortunately it occasionally induces meningitis, haemo-
thorax with empyema, etc,
If the expected effect is not obtained, some foreign body like bits of
bandage or cotton may be found inhibiting fibrinolysis. It is also noted
that mucoproteins and fibrinous or collagenous tissues cannot be dissolved
by streptokinase-streptodornase. It is of importance that the enzymes
really come into oontact with tissues directly. Therefore, it is necessary to
remove the tissue by aspiration of other means before the application of
fibrinolysin every 24 hours.
JDarenteral Therapy
Animal experiments do not give uniform results with parenteral
therapy, because the blood of some kinds of animals does not react with
fibrinolysin in the same way as in the human. The early preparations of
fibrinolysin were not pure enough for clinical use. They often provoked
fever and shock-reactions when given parenterally. In more recent years
better products have been produced making parenteral treatment more
feasible (Reports by FLETSCHER, JOHNSON and later of ENGLER, CHRISTC-
PHER, MORETZ, MOSER and KENNETH, etc). These latter authors discuss
the successful treatment of thrombosis and embolism by intravenous injec-
tions and infusions.
Intramuscular and peroral or sublingual fibrinolysin therapy with
early products did not give satisfactory results. Only in the past few years
have the good effects like those reported by Innerfield in 1958 been ob-
tained.
Intravenous fibrinolysin therapy is a new and efficient way for the
treatment of thrombosis and embolism. Fibrinolysins should not be used
instead of anticoagulants. Fibrinolysins do not replace the dicoumarin
and indanedione drugs in this regard, nor do they inhibit the expansion
of a thrombus unlike heparin. They dissolve thrombus on intravenous
injection due to fibrinolytic activity. This fibrinolytic ferment system
4
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attacks not only fibrin and fibrinogen, but also inactivates factors V,
VIII, and particularly prothrombin (Factor II). By the proteolysis of
fibrinogen with the enzymes an antithrombin is formed. This had a
strong effect. The production of this antithrombin is of great importance
in fibrinolytic therapy.
Many publications on experiences with fibrinolytic therapy exist, but
I will mention here only some results of GROSS, HARTL, KLOSS and RAHN,
and of our own with the material of I and II Streptase of BEHRING-WERKE,
Germany, (1962-1964).
1. Preparations:
Preparations which act as activators of fibrinolytic systems when
given intravenously may be divided into two groups according to their
actions:
1. Fibrinolytic agents acting directly in vivo and in vitro.
2. Those acting indirectly.
A. The direct acting substances may be divided further into:
a) Streptokinase, an activator of the fibrinolytic systems and its end.
product.
b) Active plasmin resp. fibrinolysin. This may be isolated from human
plasma by the help of streptokinase.
The new fibrinolytic preparations still contain some streptokinase, but it
is more purified to such an extent that febrile reactions are rarely encoun·
tered and if so, are harmless. Normal human urine also contains a sub.
stance having fibrinolytic activity, i. e., urokinase. It is, however, still in
an experimental stage and no clinical data are available at the present
time.
B. Substances having indirect fibrinolyti£ activity
Substances belonging to this group show no fibrinolytic activity in
vitro, but they cause in vivo activation of fibrinolytic systems by a still
unclear mechanism. These substances include
(a) nicotinic acid.
(b) adrenalin.
(c) lipopolysaccharide from some bacteria, e. g. pyrexal isolated from
salmonella equi.
(d) Oral antidiabetic drugs, e. g., tolbutamide and carbutamide.
In connection with the indirect active fibrinolytic agents, several
authors have reported good results using nicotinic acid treatment which
induces activation of the body'S own fibrinolytic system. This preparation,
already in use here in our clinic for the treatment of other diseases, is now
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found to be useful in the treatment of thrombosis and embolism. It is
particularly useful because it is unaccompanied by dangerous side effects.
I have wide experience with the preparation called .• Solcosal". It
contains fibrinolysin activating nicotinic acid and also vitamin P (Rutin)
for the protection of tone and permeability of the vessel-wall. Besides
these, "Solcosal Forte" contains also 1, 000 units of heparin per 5 m!. The
addition of heparin supports the fibrinolysin-activation and enhances the
effect of nicotinic acid on the circulation. At the same time heparin
possibly inhibits the further formation of thrombus.
2. The dosage of direct fibrinolytics
In treatment with streptokinase some patients show increased resis-
tance and others require lower dosage. Hence the determination of strepto-
kinase tolerance is important before the commencement of therapy proper.
we have several different methods for the determination of individual
dosage, e. g. the plate test of ASTRUP, and MULLERTZ, the methods of
MARBET. of WITTE and DRINBERGeR, of FISCHBAUER, etc. Among these
the thrombelastograph is the best method for such determination. The
method is as follows: In a cell of the thrombelastograph 0.23 ml of the
patient's oxalated plasma to be tested is taken. Then 10 units are added,
while coagulation after adding calcium is checked. If fibrinolysis is not
so powerful, though the greater part of fibrinogen is destroyed, a clot
will be formed. In such a case the thrombelastogram shows the form of
a pear. By observing clot formation in 3 cells containing different can·
centrations of streptokinase it is possible to determine how many units of
streptokinase are necessary to result in a complete suppression of clot 10
minutes after adding calcium. This number is the so-called "streptokinase
tolerance" according to FISCHBAUER, as applied to 0.23 ml of plasma.
The total amount of streptokinase to be injected into the patient should
be obtained by multiplying the value about 10, 000 times, but experience
has shown that this dosage of streptokinase is not adequate to obtain a
beneficial effect in vivo. Hence the "streptokinase tolerance" must be
multiplied by 30, 000 instead of I 0, 000. This will provide an effective
therapeutic dosage. With this method an expert worker takes a total of
about 20 minutes, while in contrast, with the plate.method, he may
require several hours for obtaining the same result.
The determination of the individual dosage before treatment is very
important (MARX, etc.). According to SHERRY and his associates, 596 of
the population show a significant level of antistreptokinase.
According to KOLLER and others the streptokinase tolerance may vary
6
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from 2 to 76 units and it can reach 720 units after streptokinase treatment.
Even more streptokinase will be needed for a second treatment to reach
effective lysis. The duration of therapy is also different from case to case.
It is essential to perform individual treatment in each case according to
his streptokinase tolerance.
I will not quote different theoretical and practical data concerning
this problem, but experience has shown that clinical results give the best
information for the duration of streptokinase application. Threatment
over a period of 12 hours is recommended, but according to SHERRY and
his collaborators it may be continued up to 32 hours. The dose per infusion
could be decreased in the second infusion in comparison with the initial
dose of 50, 000, but it should not be less than 20, 000-30, 000 units. It is
important after such fibrinolytic treatment to follow with anticoagulant
therapy, first using heparin and later oral anticoagulants. Some authors,
e. g., GROSS, HARTL, KLOSS and PAHN, separate compatibility and clinical
results. According to clinical experience 40, 000--100, 000 units of fibri-
nolysin per infusion gives the most successful results. The above.named
authors used in general 40, 000 nnits in 400-500 ml of glucose or saline
solution, or in smaller dosage, 200-250 ml, if necessary. The duration
of treatment is about 6 days and not more than 5-6 infusions, because,
with aging of the thrombus, lysis becomes more difficult and the host
may be sensitised with antibody formation.
GROSS, HARTL, KLOSS and RAHN, and ourselves, made the following
investigations at the beginning and at the end of infusion therapy: .
I) Thrombelastography.
2) Thromboplastin time.
3) Determination of Factor V.
4) Thrombin coagulation time.
5) Fibrinogen determination.
6) Euglobulin lysis time, and
7) Fibrin plate test (according to ASTRUP and MULLERZ). Besides
these techniques some authors also carried out fibrinogen electrophoresis.
In some patients it is desirable to check also antistreptokinase and
antistreptolysin values. BEHRING-WERKE, Germany, recommend the so-
called streptokinase resistance test for obtaining better scientific therapeu-
tic information. We have many data available on succesful treatment
with fibrinolysin in cases of thrombosis and embolism, e. g., pulmonary
embolism, cerebral thrombosis, sinus thrombosis, thrombophlebitis and
phlebothrombosis, etc. The earlier experiences in this field were published
first by twelve American authors in 1959 in the Journal of Angiology (Vol.
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10, 244). These authors used the fibrinolytic preparation, actase.
Mention must be made of Varidase (LederlejUSA and in Germany
Cyanamid GmbH, 11unich) and the excellent fibrinolysin (human),
LYOVAC von MERCK, Sharp and Dohme Inc., RAHWAY, N.J. (USA).
The latter is made by activating a fraction of human blood plasma with
streptokinase. The human plasma is fractionated by the COHN ethanol
method. One MDS unit of fibrinolysin Lyovac is the quantity which is
sufficient to dissolve within 10 minutes a clot of about 5 mg. weight under
constant conditions of PH, temperature and molar concentration. We
have also other valuable and excellent preparasions like Streptase of
Behring in Germany. In haemorrhagic disorders and including afibrino-
genaemia fibrinolysin therapy is contra.indicated.
3. Indidations for fibrinolysin therapy:
According to our present-day knowledge, the indications for fibrinoly-
sin therapy are as follows: -
1. Acute venous thrombosis. Several authors have reported dissolu-
tion of venous thrombi in arms and legs when fibrinolysin therapy is used.
2. Fresh pulmonary emboli.
3. Arterial thrombosis and embolism. As reported by KOLLER and
other authors, not only is the success of therapy dependent on the age of
the thrombus, but also on consecutive necrosis of the infarct. The occlu.
sion of arteries or veins in the brain for some minutes gives rise to irrever-
sible damage-similarly in coronary thrombosis after two hours and in the
arteries of the extremities after 6 hours. After these periods the infarct
does not recover even though the embolus is dissolved. Some authors have
reported the dissolution of microthrombi in the vicinity of the infarct, thus
preventing further tragedy.
It is possible to commence fibrinolytic therapy some hours after the
formation of the infarct. However, several authors (AMBRUS, FISCHBACHER,
JURGENS, MARX, FLETSCHER, etc.,) reported rather poor response to
fibrinolysin therapy in the treatment of arterial thrombosis and emboli
under these conditions.
Contra-indications:
Contra-indications may be divided into two categories:
(a) Those in which fibrinolytic therapy is not effective and
(b) Those in which fibrinolytic therapy could be dangerous.
The first group contains cases with thrombosis and emboli older than
3 days and the second group those with ulceration, wounds, operative
procedures and haemorrhagic disorders. Fever associated with coronary
8
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thrombosis or circulatory disturbance associated with pulmonary emboli
are not contra.indications to therapy. Side effects, especially haemorrha·
ges, can be treated with fibrinolysin antagonists. Modern therapeutic
fibrinolytic therapy, especially of thrombosis and emboli is relatively
harmless. As already pointed out, the most important and dangerous side
effect seen in these cases is h:lemorrhage. Complications such as high
fever have seldom been encountered in recent years. With therapeutic
doses of fibrinolysin, fibrinogen disappears as in afibrinogenemia, but
Factors V, VIn and prothrombin are acarcely influenced. A severe
decrease in platelets does occur. If, in spite of all measures taken, a
haemorrhagic tendency appears, patients should te treated with an ex·
cellent fibrinolysin antagonist, viz. E-aminocaproic acid in dosage of 30
gr. per os or several grams intravenously. This treatment will effectively
inhibit haemorrhage in a few minutes.
E-aminocaproic acid is in the first place an activator and in the second
an antifibrinolysin. The mechanism of action is according to the opinion
of several authors a competitive inhibition. E-aminocaproic acid as shown
in Fig. 1, is a physiological amino acid. This was discovered by Japanese
investigators and first used by my friends T. ABE and K. HAYASAKI, T.
ABE and K. SATO, etc. In Europe P. de NICOLA, SOARDI, GIBELLI, KOLLER
and SZIRMAI were the first to work with this compound. Besides E-amino.
caproic acid and some other aminoacids we have the inhibitor from pan.
creas (TRASYLOL-BAYER in Germany) and soya inhibitor. KLINE, SHERRY,
FLETSCHER, GROSS, HARTL, KLOSS and RAHN reported on side effects of
fibrinolysin infusion as follows: headache, painsin joints, shivering, rest-
lessness and hypotonia. According to thc experience of these authors, well
controlled fibrinolytic therapy is no greater risk in relation to haemorrhage
than is the case with anticoagulant therapy. However, it must be stressed
again that thrombolysis by fibrinolysin does not work in the same way as
in thrombosis. Therefore, it is very important to combine fibrinolytic
therapy with very careful coagulation controls by using anticoagulants.
Fig. 1
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Similarities of fibrinolysin antagonist, E-aminocaproic acid to leucine
and lysine.
Our Experiences:
The author has made researches and treatment since 1961 with
Varidase or fibrinolysin Lederle. So-called ,. Buccal" tablets (1 Tabl. =
10, 000 U. streptokinase and 2, 500 U. streptodornase, bottles with 25, 000
U from these 20, 000 U. streptokinase, 5,000 U. streptodornase for injec-
tions and different buccal tablets). These compounds obtained from
Lederle/USA and Lederle Cyanamid/Munich, were also used for research
purposes. Broad outline of practical and experimntal data follow.
Some of this work has been reported at the 8th Congress of the
European Society of Haematology in Vienna (1961), to the World Con-
gress for Gynaecology and Obstetrics in Vienna in 1961, the Congress of
the Swiss Society of Haematology in Lugano in 1962, the Congress of the
European Society of Haematology in Strasburg in 1965 and in some publi-
cations (1955, 1956, 1962, 1963 and 1964). I gave some lectures at the
Universities in Wurzburg, Zurich, Madrid, Helsinki, and some American
universities (1965), and these data will be described briefly here.
Varidase Buccal-tablets were given to 195 patients. Among these
127 patients had phlebitis and thrombophlebitis of different aetiologies
(rheumatic, traumatic, and infectious). 51 patients with chronic tonsillits,
pharingitis and laringitis, and 17 patients with different skin infections
were treated. Also treated were 10 cases of repeated furunculosis and 25
patients with thrombotic states, such as varicose ulcer.
Included are all those treated up to 1965. Treatment varied from
case to case and some patients have also been treated in combination with
other drugs. In Table II are brief descriptions of some cases. By com-
parison, data obtained by experience in the past twenty years with other
treatments of the same diseases are poor. Among 127 cases of thrombo-
phlebitis and phlebothrombosis 122 patients were successfully treated with
medicaments. Quicker healing, resolution of post-thrombotic oedema and
quicker reduction of inflammation were obtained. The patients treated
in combination had butazolidin, phenylenedandione and dicoumarin
preparations, heparin, hirudoid, cortisone and antibiotics, Naturally,
strict indications and contra-indications were followed. Controls of blood-
clotting factors and liver function, etc., were made. In 44 patients with
pharyngitis laryngitis, and a variety of forms of tonsillitis, also had very
good and quick recovery. Patients who have been sick fora long time
should also be treated. Quick healing was noted in 8 patients with celluli-
10
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tis, 7 of 10 patients with furunculosis and 21 cases with varicose ulcer,
and other 8 post-thrombotic states.
Together with the results of my later experiences it could be said that
Varidase (Streptokinase-Streptodornase) treatment is very effective in in-
flammatory thrombophlebitis and phlebothrombosis, varicose ulcer and
thrombotic states. It may also be added that colleagues have had similar
results when advi£ed by me.
My experiments with fibrinolysin plasmin and blood-clotting factors
including platelets in health y and sick persons are reported as follows:
METHODS, MATERIALS AND PATIENTS:
Examinations of activators and inhibitors have been made using the method
of DUCKERT and KOLLER, as well as our own method published elsewhere.
Platelet determinations were made using the method of SPITZ, FEISSLy and
LUDIN. For determining the effect of fibrinolysin on blood clotting factors we
used oxalated plasma at 37°e in blood clotting thermostat as devised by the
author in 1953. The plasma was incubated with 400 units/ml. fibrinolysin at
37°e. in the thermostat. At varying lapses of time blood samples were taken.
The coagulant fibrinogen and the physiological activity of blood-clotting factors
in experimental solutions or in the patient's blood have been observed. The
method described by FONIO using citrated plasma was used for platelet determi-
nations. For the examination of the degree of fibrinolytic effect (1) citrated
plasma from 8 healthy women (not pregnant) between the ages of 25 and 30
years were used as a standard. Repeated investigations were made on these
during a period of 10 days. (2) Plasma from eight normal people having no
haematological disorder were used on the second day of the period. (3) Plasma
from seven patients with acute venous thrombosis prior to treatment with drugs
was investigated. (4) Plasma from 6 patients with thrombocytopoenia WERLHOF'S
Disease) were investigated.
RESULTS
In the experiments with normal bloodplasma the formation of fibrino-
gen war complete:! by 27 minutes. Besides fibrin formation we also
checked plasma Factors V and VII, both of which showed initial activa·
tion at 65-100 minutes. Thereafter they had lost their physiological
functions. The data are consistent with those reported by JUNG, DUCKERT
and KAPELLER. Factors VII, IX and X are stable, and showed no change
in plasma or in serum even in thepresence of fibrinolysin. Prothrombin
was diminished by 50 to 60 %. I also found an increase in heparin-like
antithrombin due, according to JUNG and DUCKERT, to reduction in
fibrinogen. The number of platelets dd not change significantly, as was
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revealed by checking the sediment of the oxalated plasma incubated with
400 unitsjml. of fibrinolysin at 37°C.
Experiments with blood and plasma taken at this time revealed
slightly reduced levels of platelet numbers and prothrombin initially, but
the level of antithrombin was twice as high as previously.
My earlier experiments in 1961-1962 indicated that this could be
explained by an increasein fibrinolytic effect and in the tendency to
haemorrhage.
In 7 patients suffering from acute venous thrombosis there was no
fibrin formation at the beginning of treatment during 38 minutes. Factor
V needs 80 minutes and AHG 65 minutes on an average for the loss of
their physiological functions. Prothrombin was reduced to a level of 60-
7096, but antithrombin inereased during a period of 38 minutes by about
the same rate as is seen in healthy persons after the fibrinolysin effect. We
thought that we would have had a slower value similar to thrombosis
without fibrinolysis effect. The number of platelets was not significantly
changed.
In the experiment with blood from those patients suffering with
thrombocytopenia (Werlhof's disease) fibrinolysin effected a quicker
reduction in fibrinogen level after about 16 minutes, especially marked in
4 cases. Factors V and VIII had also lost their physiological function
after 40-80 minutes. Prothrombin was reduced by 65-73 % and the
quantity of antithrombin was twice as high as in normal plasma. The low
platelet count of the patients with thrombocytopoenia was further reduced
by 20 % in 4 patients and by 15 % in 2 further patients, by the effect of
fibrinolyin. All the experiments were made under strict aseptic conditions
using the method of FONIO with citrated plasma in reagent tubes. The
decrease in thrombocyte count by fibrinolysin was as rapid as in healthy
persons on the second day of the period and as in the patients with
thrombosis.
DISCUSSION
My experiments have shown that there are differing fibrinolytic
effects on clotting factors and on antithrombin formation in healthy per·
sons during and after the period of thrombocytopoenia and thrombosis.
This effect is very important especially during the period of thrombo.
cytopoenia in relation to the activation of fibrinogen, factors V and VIII
and the partial activation of prothrombin becoming more rapid, while
the antithrombin is significantly higher. By some thromboses fibrinolytic
12
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effect is also decreased by the already-named factors, but the antithrombin
level is not always less than normal.
According to FONIO, the effect of fibrinolysin can be measured by
the degree of retraction of fibrin clot and by the degree of reduction in
platelet count. These experiences also seem· to confirm my observations
that thrombocytopoenia and during the period, fibrinolytic decrease is
more rapid. It may be worthwhile mentioning thc experiments of A.
KAPERT on fibrinolysin and blood clotting. He examined before and
during treatment at varying times the blood of 39 patients (22 0', 17 ¥)
Middle age: 59, 5 yearr (43-72 years old).
These patients suffered from the following diseases:
Nine patients had obliterative arteriosclerosis (Stage II-III) of the
extremities of brain vessels.
Eight patients had acute or sub-acute thrombosis of femoral and
carotid arteries.
Eight patients had infarcts of heart and post-infarction states.
Two patients had "myopathia cordis".
Two patients had pulmonary emboli.
Two patients had thrombophlebitis and phlebitis of varicose veins.
Four patients had post.thrombotic syndromes.
Six different patients had other diseases.
All these patients were divided into three groups, viz. A, Band C.
Group A: Peroral application 3 times/day, 1 or 2 dragees. Two
patients were treated with mean daily doses of 100 mg. Duration of treat.
ment was 3-4 weeks. During the trial time 12 patients also took Dicoumo-
ral (Marcumar).
Group B : Parenteral administration to 12 patients. Injections of 100
mg. i. m. twice daily in 6 cases, 3 times daily in two cases and once daily
in one case. The mean daily dose was 200 mg. Duration of treatment was
8-10 days.
Group C : Patients were treated with rectal application as suppositories,
100 mg of effective elements, 200 mg, once in the morning and also in the
evening, per day. Duration of treatment was 8-10 days.
During the oral (100 mg per day) and reetal (200 mg per day) therapy
he observed marked reduction of euglobulin-lysis time. With both forms
of application a good effect was observed in 30 % during treatment.
Nearly the same effect qualitatively and quantitatively was obtained with
parenteral application of 100-200 mg per day. With qualitative technique
(total-lysis of plasma clot or total-blood) one has only few really positive
13
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reactions. Examination of blood.clotting (method of LEE and WHITE,
test of heparin-tolerance, test of thromboplastin-tolerance) have shown
measurable effects which have little anticoagulant action by all forms of
application. The prothrombin index was not significantly influenced.
The reactions observed in the test of heparin-toleranee using the oral
application are very interesting.
Fibrinolysis in Paediatrics :
In general, all that has been mentioned above about fibrinolysis and
thrombolysis is applicable to paediatrics, although the dose has to be
modified as in all other fields of medicine. Preparations of fibrinolysins
are used in various fields 'of paediatrics such as surgery, oto-rhino-laryn-
gology, dental surgery and treatment of accidents.
Successes have been reported by several authors in the treatment of
sagittal sinus thrombosis of the new-born with streptase/Behring. Good
results have also been reported in post.operative mesenteric occlusion of
veins using Streptase and Varidase and in adults with Varidase, and in
arterial or central venous thromboses after accidents both in adults and
children with Streptase and Varidase,
In 1962 at a meeting of paediatricians in Leipzig, KAKDLER reported
on the treatment of purulent meningitis with streptokinase-streptodornase.
He observed marked amelioration of the thick cerebro-spinal fluid using
Varidase by intrathecal or lumbar application. The thick cerebo.spinal
fluid was thinned by Varidase which makes it possible to obtain C. S. F.
by puncture. As the C. S, F. is liquified by Varidasse very quickly it is of
great help in treatmcnt with antibiotics which are made to disperse quickly.
Four doses of 10,000-15,000 units are recommended for newborn children
and 20, 000-25, 000 units for little children. One makes a puncture 6
hours after the application and the thin C. S. F. can be released. It is
possible to give immediately another instillation of Varidase. The Varidase
can be continued for a week. Generally, treatment with Varidase is com-
bined with antibiotic treatment.
KOHNLEIK also describes the use of Varidase in osteomyelitis (1962).
He recommends the use of Varidase.Buccal especially in chronic osteomy.
elitis in order to dissolve fibrin around the inflammatory focus, thus,
making it easy for antibioties to permeate into the focus. By using broad
spectrum antibiotics sasisfactory healing was hastened in the patients
treated with Varidase.
The number of cases of chronic osteomyelitis increased from 20-40%
in combined treatment with Varidase. Complete healing of acute osteo-
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myelitis in the era before antibiotics was 8 %, 64 % during the penicillin
period and 76 % with wide spectrum antibiotics only.
MAPPES and YOLK reported also on general and local antibiotic long-
term treatment of post.thrombolytic osteomyelitis of several cases in adults
and children. He discussed the treatment of the disease with Varidase in
cembination with Ledermycin. According to MILLER, GODFREY, MILTOK,
GINSBERQ and PAPASTRAT who reported on their clinical experiences with
Buccal Streptokinase treatment with Buccal Varidase effects a more rapid
reduction of oedema by quick dissolution of fibrin sediment resulting in
suppression of the inflammatory process. Varidase Buccal could also be
used for prophylaxis of oedema and is very helpful in operations on the
face and mouth. The oedema inhibits wound.healing both in adults and in
children and the application of Varidase Buccal in combination with anti-
biotics promotes wound.healing. Thus Varidase is useful in a variety of
conditions, viz. abscesses, haematoma, oedema (post-operative and post-
traumatic), thrombophlebitis, various infections, operations of all kinds,
amputations, etc.
MANNEL reported the fermentative dissolution of necrotic tissues by
Varidase. According to him, Varidase Buccal ameliorates the application
of Varidase because of its optimal effect and because it is simplest in the
way of application.
But already in 1958 INNERFIELD reported at the Meeting of the
American Medical Association that both in adults and children Varidase
reduces the duration of the inflammatory reaction of patients by its
Buccal application. The human organism reacts to trauma with an in
flammatory response so as to localise the various toxins.
Besides these, experimental observations revealed that the Schwartz-
mannphenomenon is inhibited by Varidase. Clinical examination shows
that the tuberculin reaction is largely suppressed by Varidase. In patients
with urticaria, contact dermatitis and bronchial asthma their allergic
symptoms were improved by the buccal application of Varidase.
Varidase also proved to be effective for periorbital oedema, haemato-
mas and ecchymosis due to trauma of face and head, acute inflammation
of joints and oedema following injuries and in thrombophlebitis inrelation
to operations. Besides investigatiog the clinical value, we have made some
experiments on animals with Buccal Varidase in combination with anti·
biotics in the treatment of experimentally induced abscesses and cellulitis.
Among these observations a marked effect was obtained on staphylococcus
infection, although infections were often multiple.
Forty.eight hours after the application of Varidase Buccal (1 tablet
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every 4 hours), the inflammatory focus showed a tendency to localisation
of purulent exsudate so that it was easily removed by incision and drainage.
In acute infections of the respiratory tract the sputum was lipuified and
coutd be coughed up very easily. Chronic bronchitis showed an increase
in weight, improved feeling of well-being and a better sleep record.
WEGNER in Munich reported on the possibility of avoiding post-opera.
tive complications in plastic surgery: post-operative haemorrhage, haema-
toma and oedema. For many years these post-operative complications
were a big problem in plastic surgery, esrecially in children, and it was
very difficult to avoid them in spite of careful operations. Therefore,
Varidase treatment is very important in this field. It promotes physiologi-
cal phagocytosis and regeneration in the healing-process of wounds by
dissolution of fibrin, by the resorption of the viscous exudates and by the
diminution of capillary bleeding and venous stasis.
HEIDSIECK and GABKA reported in 1962-1963 on the application of
Varidase in thc field of dental surgery in both children and adults. In
this field- extraordinarily good effects were observed in the cases of infec-
tion treated with Varidase, especially when combined with antibiotics.
About one half of the cases treated with Varidase showed very puick
amelioration of symptoms by the sccond day of treatment.
BETHGE, HORATZ and STURTZBECHER reported on the intrapleural use
of streptokinase.streptodornase in post-operative empyema of adults and
children. They treated 60 patients with post.operative empyema with
Varidase. By adequate application of Varidase they could successfully
inhibit the formation of fibrin, blood clots and the purulent process.
Those already formed could be dissolved. Thus an excellent effect was
observed in 32 cases out of 60 patients. Four teen showed moderate
improvement and there was no recognizable effect on the remainder. In
the cases refractory to treatment they did not find that the streptokinase-
streptodornase was of inferior quality. Hence its ineffectiveness is probably
due to some other factor.
EAGLE reported on Varidase Buccal treatment of oedema in the oto-
rhino-laryngology field both in adults and children. The application of
ferment· preparations obtained since 1949 showed a very good effect when
given by local, intravenous, intramuscular and oromucal routes in dental
extractions, tonsillitis, purulent otitis media, haematoma of the tongue
and various kinds of dermats.
BLAHA and WORN reported on the fermentative breakdown of extra-
pleural and intrapleural haemothorax by Varidase. Its good effect was
shown in most cases when the haematoma di ssolved after one or two
16
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injections.
Many other excellent papers and books have been published on
fibrinolysis in the last decade, but this paoer may serve as a brief sum-
mary of our up-to-date knowledge in this field of study.
SUMMARY
The author has described modern thrombolytic therapy of arterial
and venous thrombosis and emboli by therapeutic fibrinolysis and other
drugs also methods and effects of local and parenteral application of
fibrinolysin preparations, dosage, control, indications. Contraindications,
side-effects and their treatment with fibrinolysin antagonists and therapy
with fibrinolysin combined with anticoagulants and antibiotics are dis-
cussed.
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